Problem · updated 2026-11-20

Heart disease

The leading cause of death worldwide: 9,469,357 deaths from ischaemic heart disease in 2023.

Every number below has a source · Download this data

The numbers

Updated 2026-11-20 · CSV · JSON

Heart disease

people living with ischaemic heart disease

112M183M254M254M1990200020112021
112.2M159.5M206.9M254.3M254.3M1990200020112021
Data table
YearValue
1990112,169,488
2021254,276,268
Liang et al., Frontiers in Public Health, 2025, from GBD 2021. Cases rose from 112,169,488 in 1990 to 254,276,268 in 2021. WHO deaths rose over the same era, from 6,429,003 in 2000 to 9,469,357 in 2023. · As of 2026-11-20

Neglectedness

3

score out of 10. Higher means more neglected.

WHO Global Health Estimates 2023 deaths workbook; SELECT, NEJM

As of 2026-11-20

Tractability

7

score out of 10. Higher means effort buys more progress.

SELECT and VESALIUS-CV, New England Journal of Medicine

As of 2026-11-20

What you can do

Open data

Build

Startups, labs, open work

  • Startup

    Cleerly

    Builds FDA-cleared software that reads coronary plaque and stenosis from CT. An updated Cleerly LABS was cleared on 30 October 2026.

    Checked 2026-11-20

  • Startup

    Cuorips

    Japan conditionally approved its iPSC-derived cardiomyocyte sheet on 6 March 2026 for severe ischemic heart failure.

    Checked 2026-11-20

Fund

Grants, prizes, funders

None yet.

Buy

Products to use or back

  • Product

    Cleerly LABS

    Coronary CT analysis software. The FDA cleared an updated version, including the PLAQUE algorithm, on 30 October 2026.

    Checked 2026-11-20

Learn

Explainers and papers

  • Paper

    VERVE-102

    Phase 1 study of VERVE-102, a base-editing therapy designed to inactivate PCSK9 in the liver. NEJM, 2026.

    Checked 2026-11-20

  • Paper

    CTX310

    Phase 1 trial of CTX310, a CRISPR-Cas9 editor aimed at hepatic ANGPTL3. NEJM, 2025.

    Checked 2026-11-20

  • Paper

    SELECT

    Weekly semaglutide reduced major cardiovascular events versus placebo in people with cardiovascular disease and overweight or obesity, without diabetes. Hazard ratio 0.80.

    Checked 2026-11-20

  • Paper

    VESALIUS-CV

    Evolocumab in people without a prior myocardial infarction or stroke. The primary 3-point MACE hazard ratio was 0.75.

    Checked 2026-11-20

  • Paper

    Lp(a)HORIZON

    Pelacarsen lowered lipoprotein(a) and did not reduce major cardiovascular events. Hazard ratio 1.02.

    Checked 2026-11-20

  • Paper

    ZEUS

    Ziltivekimab lowered interleukin-6 and did not reduce cardiovascular events versus placebo. Hazard ratio 0.99.

    Checked 2026-11-20

  • Government

    WHO Global Health Estimates

    Downloadable death counts by cause, age, and sex for 2000 through 2023, from Global Health Estimates 2023.

    Checked 2026-11-20

The burden behind it

9.5Mdeaths a year in the causes this problem addresses

Ischaemic heart diseaseWHO #1 in 2023

LDL-driven plaque narrows the coronary arteries over decades. A plaque ruptures, a clot forms, and heart muscle downstream dies. Blood pressure, cholesterol, smoking, diabetes and age drive it.

Counted only under heart disease. Hypertension keeps stroke, and longevity keeps stroke and dementia. These 9,469,357 deaths are not added to either of those problems.

9.5M15.5% of all deaths

Deaths in the causes this problem addresses, from WHO 2021 and GBD 2023. Not deaths this problem would prevent. A cause shared by two problems is counted under both, so sums across problems overlap.

Sources: WHO Global Health Estimates 2023, global deaths workbook (published 2026): ischaemic heart disease, both sexes, all ages, 9,469,357 deaths in 2023. The public fact sheet rounds the same estimate to 9.5 million. Checked 2026-11-20.

Why it is not solved yet

Biggest blocker

Ischaemic heart disease deaths are still rising even though some approved drugs already reduce cardiovascular events in trials.

  • WorkRead SELECT and VESALIUS-CV next to Lp(a)HORIZON and ZEUS before treating a biomarker change as fewer deaths.
  • FundFund a program that measures whether people at high risk actually receive a drug that already reduced events in a trial.
  • RunIf you run a clinic, count how many eligible patients are on a therapy with a positive cardiovascular outcome trial.
Why, and how we know

WHO counts 6,429,003 deaths in 2000 and 9,469,357 in 2023. SELECT and VESALIUS-CV reduced events. Inference: the binding constraint is not the absence of a first effective drug. How much of the rise is untreated risk, ageing, or a mechanism those drugs do not touch was not separated in this pass.

Wrong if: A later WHO edition shows ischaemic heart disease deaths back at the 2000 count, or the event reductions in SELECT and VESALIUS-CV fail to replicate.

Found: Lp(a)HORIZON and ZEUS, both published in 2026, did not reduce cardiovascular events (hazard ratios 1.02 and 0.99). Lowering lipoprotein(a) and interleukin-6, in those two trials, was not enough.

On it: SELECT investigators, VESALIUS-CV investigators, Lp(a)HORIZON investigators, ZEUS investigators

WHO Global Health Estimates 2023, global deaths workbook (checked 2026-11-20) · SELECT trial of semaglutide, NEJM · VESALIUS-CV trial of evolocumab, NEJM · Lp(a)HORIZON trial of pelacarsen, NEJM · ZEUS trial of ziltivekimab, NEJM

Companies working on this

0 sourced companies. Links are the company page or the source already on file.

No sourced company is on file.

Industry sponsors on active trials

183 distinct industry sponsors. Each link is the query for that sponsor. Top names by trial count.

Company affiliations on recent papers

OpenAlex stops at 200 institutions for this query, so the count is not in the score. These are the top names from that capped list.

Supply and demand

This score does not change the priority rank. Demand 56. Supply 37. Gap 19.

  • Related deaths / yr: 9,469,357 deaths/yr Source
  • Burden feed: not yet sourced
  • OpenAlex works, last 12 months: 5,785 works Source
  • NIH RePORTER funding: 316,484,990 USD Source
  • OpenAlex company affiliations: count capped Source
  • ClinicalTrials.gov active trials: 2,265 active trials Source
  • ClinicalTrials.gov industry sponsors: 183 industry sponsors Source
  • Federal Register documents: not yet sourced
  • USAspending awards: 125 awards Source
  • SEC EDGAR Form D filings: not yet sourced
  • openFDA current drug shortages: not yet sourced
  • Wikipedia pageviews (attention, not demand): 692,372 pageviews Source
  • Sourced companies on file: 0 companies
  • Sourced founders: 0 founders
  • Sourced funders: 0 funders
  • Annual capital: not yet sourced

Who is moving on Heart disease

A human checks every entry. Nothing here can be bought.

Open starts

0 willing to start

0 so far. Be first.

Open joins

0 want in

No companies tracked yet.

Open capital

0 allocators watching

0 so far. You can stay anonymous.

Act on Heart disease

What exactly

0 / 600

A human reviews every submission. Nothing publishes itself.

Cite this

Year mismatch: Deaths are WHO Global Health Estimates for 2023. Prevalence is GBD 2021, as reported in 2025.

  1. optimism.fun. (2026). Heart disease. https://optimism.fun/p/heart-disease
  2. NCHS Vital Statistics Rapid Release No. 44 (July 2026): heart disease was the leading cause of death in 2025, with 694,708 deaths. Provisional data as of 10 May 2026. This is all heart disease, not the global ischaemic heart disease count. (2026). US heart disease deaths, 2025, provisional: 694,708. https://www.cdc.gov/nchs/data/vsrr/vsrr044.pdf
  3. WHO Global Health Estimates 2023, global deaths workbook. https://cdn.who.int/media/docs/default-source/gho-documents/global-health-estimates/deaths_global_2026-09-30.xlsx
  4. WHO, The top 10 causes of death (2 October 2026). https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
  5. Liang et al., global burden of ischaemic heart disease, GBD 2021. https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1569179/full
  6. SELECT and VESALIUS-CV, New England Journal of Medicine (2026). Tractability. https://www.nejm.org/doi/full/10.1056/nejmoa2307563
  7. Liang et al., Frontiers in Public Health, 2025: 254,276,268 prevalent cases in 2021, from GBD 2021 (2021). people living with ischaemic heart disease: 254,276,268. https://doi.org/10.3389/fpubh.2025.1569179 https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1569179/full